Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001

GD Demetri, L Paz-Ares, AF Farago, SV Liu, SP Chawla, D Tosi, ES Kim, CM Blakely, JC Krauss, D Sigal, L Bazhenova, T John, B Besse, J Wolf, T Seto, E Chow-Maneval, PS Multani, A Johnson, B Simmons, RC Doebele